Renowned for supporting small pharmaceutical and biotechnology companies and medical departments at universities, BOYDShelps clients across the globe to translate their research ideas into medicines to treat human diseases.
Established in 2005 by Professor Alan Boyd, Boyds provides a range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products. The company started with an office in Crewe, Cheshire, and subsequently opened an office in Cambridge in 2009. It now has a team of ten full time staff and several associate consultants who work across the whole range of medicines development, including product development, regulatory affairs, manufacturing, toxicology, pharmacovigilance and medical monitoring.
The company has extensive experience in developing pharmaceutical and biological products covering multiple treatment approaches. In particular, Boyds specialises in the development and commercialisation of cell and gene therapy products. This also includes rare and orphan disease indications. Boyds’ unique and extensive experience in relation to cell and gene therapy products adds value to the company’s proposition. Professor Boyd has particular expertise in this area and developed the first gene-based therapy that was submitted to the Medicines Regulatory Authority in Europe for approval.
WORKING WITH STARTUPS
In attracting new clients, Boyds’ strategy has been to work initially with medical departments in universities that have research ideas for new therapies to treat human disease, and their readiness to take the first steps along the medicines development pathway. Working with the medical department to outline the steps to be taken, Boyds helps to identify ways to navigate around possible challenges, as well as helping to raise the funding needed to pay for early development work.
Boyds then provides support using its expert staff to advise on the manufacture of the product, the pre-clinical assessments, the clinical study activities and the regulatory approvals for the work from the relevant Government health agencies, ensuring that any development work undertaken will be compliant for the eventual marketing of the product in the key markets.
Much of this work typically results in the academic institution concerned spinning out a company from the organisation and establishing a stand-alone enterprise.
A GLOBAL INDUSTRY
The pharmaceutical industry is a global industry and it is no longer possible to develop a medicinal product in just one country, mainly due to cost and scale of the work that needs to be undertaken to get a medicine to market. Therefore, to succeed in developing medicines for patient benefit, there is a need to collaborate globally.
Boyds actively supports clients in the USA, Canada, Europe, Japan, Australia and Israel who are developing medicinal products across multiple therapeutic areas. These are major markets for pharmaceutical development and commercialisation. Boyds also works for companies and academic institutions that are located in countries that have a strong science and medical base and whose government encourages entrepreneurship to help SME development.
Boyds has seen consistent growth in turnover, with over 60% of revenue now coming from overseas clients and anticipates this trend to continue, with the clear vision to continue to use its knowledge and expertise to help clients to develop products for the benefit of patients.
Cheshire Office: Electra House, Crewe Business Park, Crewe, Cheshire CW1 6GL
Cambridge Office: Unit M, South Cambridge Business Park, Babraham Road, Sawston, Cambridgeshire CB22 3JH
Tel: +44 (0)1270 270010